Condition: Eosinophilic Asthma · Sponsor: AstraZeneca
This study evaluates the efficacy and safety of benralizumab as an add-on therapy in uncontrolled eosinophilic asthma participants treated with medium-dose ICS-LABA compared to the conventional treatment step of escalation of inhaled therapy to high-dose ICS-LABA.
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
| Research Site | Chandler, Arizona, United States | Withdrawn |
| Research Site | Sun City, Arizona, United States | Recruiting |
| Research Site | Tucson, Arizona, United States | Recruiting |
| Research Site | Bakersfield, California, United States | Not Yet Recruiting |
| Research Site | Inglewood, California, United States | Recruiting |
| Research Site | Modesto, California, United States | Not Yet Recruiting |
| Research Site | Newport Beach, California, United States | Recruiting |
| Research Site | Pasadena, California, United States | Recruiting |
| Research Site | Denver, Colorado, United States | Withdrawn |
| Research Site | Cape Coral, Florida, United States | Recruiting |
| Research Site | Hialeah, Florida, United States | Not Yet Recruiting |
| Research Site | Lauderdale Lakes, Florida, United States | Recruiting |
+ 148 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06750289